SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE

1 . A solid form of Compound 1:

wherein the solid form is of Form C.

2 . The solid form of claim 1 , wherein the solid form is substantially free of impurities.

3 . The solid form of claim 1 or 2 , wherein the solid form is a crystalline solid substantially free of amorphous Compound 1.

4 . The solid form of any one of claims 1-3 , further characterized by having at least 3, 4, 5, or 6 peaks of an X-ray powder diffraction pattern (XRPD) of FIG. 16 (bottom trace).

5 . The solid form of claim 4 , further characterized by having at least 3 of the highest amplitude peaks of the XRPD of FIG. 16 (bottom trace).

6 . The solid form of claim 4 , further characterized by having at least 4 of the highest amplitude peaks of the XRPD of FIG. 16 (bottom trace).

7 . The solid form of claim 4 , further characterized by having at least 5 of the highest amplitude peaks of the XRPD of FIG. 16 (bottom trace).

8 . The solid form of any one of claims 1-3 , further characterized by having at least 3, 4, 5, or 6 peaks of an X-ray powder diffraction pattern (XRPD) of FIG. 10 .

9 . The solid form of claim 8 , further characterized by having at least 3 of the highest amplitude peaks of the XRPD of FIG. 10 (top trace).

10 . The solid form of claim 8 , further characterized by having at least 4 of the highest amplitude peaks of the XRPD of FIG. 10 (top trace).

11 . The solid form of claim 8 , further characterized by having at least 5 of the highest amplitude peaks of the XRPD of FIG. 10 (top trace).

12 . The solid form of any one of claims 1-3 , wherein the solid form exhibits an X-ray powder diffraction pattern (XRPD) that is substantially similar to that of FIG. 10 (top trace) or FIG. 16 (bottom trace).

13 . The solid form of any one of claims 1-12 , further characterized by a TGA analysis of mass loss between 165° C. and 175° C.

14 . The solid form of any one of claims 1-13 , further characterized by a DSC comprising a peak onset at about 247° C.

15 . The solid form of any one of claims 1-13 , further characterized by a DSC substantially as shown in FIG. 12 .

16 . The solid form of any one of claims 1-13 , further characterized by a DVS isotherm substantially as shown in FIG. 13 .

17 . A solid form of Compound 1:

wherein the solid form is of Form A.

18 . The solid form of claim 17 , wherein the solid form is substantially free of impurities.

19 . The solid form of claim 17 or 18 , wherein the solid form is a crystalline solid substantially free of amorphous Compound 1.

20 . The solid form of any one of claims 17-19 , wherein the solid form is a hydrate.

21 . The solid form of claim 20 , wherein the solid form is a monohydrate.

22 . The solid form of claim 20 , wherein the solid form is a dihydrate.

23 . The solid form of claim 20 , wherein the solid form is a trihydrate.

24 . The solid form of any one of claims 17-23 , further characterized by having at least 3, 4, 5, or 6 peaks of an X-ray powder diffraction pattern (XRPD) of FIG. 4 (bottom trace) or FIG. 5 .

25 . The solid form of claim 24 , further characterized by having at least 3 of the highest amplitude peaks of the XRPD of FIG. 4 (bottom trace) or FIG. 5 .

26 . The solid form of claim 24 , further characterized by having at least 4 of the highest amplitude peaks of the XRPD of FIG. 4 (bottom trace) or FIG. 5 .

27 . The solid form of claim 24 , further characterized by having at least 5 of the highest amplitude peaks of the XRPD of FIG. 4 (bottom trace) or FIG. 5 .

28 . The solid form of any one of claims 17-23 , characterized by having an X-ray powder diffraction pattern (XRPD) that is substantially similar to that of FIG. 4 (bottom trace) or FIG. 5 .

29 . The solid form of claim 24 , further characterized by having at least 3 of the highest amplitude peaks of the XRPD of FIG. 5 .

30 . The solid form of claim 24 , further characterized by having at least 4 of the highest amplitude peaks of the XRPD of FIG. 5 .

31 . The solid form of claim 24 , further characterized by having at least 5 of the highest amplitude peaks of the XRPD of FIG. 5 .

32 . The solid form of any one of claims 17-31 , further characterized by a TGA analysis of mass loss between 65° C. and 130° C.

33 . The solid form of claim 32 , wherein the TGA is substantially as shown in FIG. 7 .

34 . The solid form of any one of claims 17-33 , characterized by a DSC comprising peak onsets at about 91° C., 103° C., and 245° C.

35 . The solid form of claim 34 , wherein the peak onset consists essentially of 245° C.

36 . The solid form of claim 34 , characterized by a DSC substantially as shown in FIG. 7 .

37 . A solid form of Compound 1:

characterized in that the solid form is of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, or Form J.

38 . The solid form of claim 37 , wherein the solid form exhibits peaks or other physical properties as shown in any one of FIG. 1 to FIG. 42 .

39 . A pharmaceutical composition comprising the solid form of any one of claims 1-38 and a pharmaceutically acceptable carrier, excipient, or adjuvant.